Literature DB >> 15536597

Is there any link between insulin resistance and inflammation in established preeclampsia?

Risto Kaaja1, Hannele Laivuori, Pekka Pulkki, Matti J Tikkanen, Vilho Hiilesmaa, Olavi Ylikorkala.   

Abstract

Both insulin resistance and inflammation may contribute to the onset of preeclampsia. They also could be interrelated. We studied the relationship between inflammatory cytokines and markers of insulin resistance. During their third trimester, 22 proteinuric preeclamptic women and 16 normotensive controls underwent intravenous glucose tolerance test (minimal model). Preeclamptic women were more insulin-resistant (P = .009), and they had higher levels of serum soluble tumor necrosis alpha receptor II (TNFalpha RII) (P = .002), triglycerides (P = .006), uric acid (P = .001), and leptin (P = .002) than did the controls. However, the study groups did not differ in serum TNFalpha, C-reactive protein (CRP), interleukin-6 (IL-6), sex hormone-binding globulin (SHBG), and high-density lipoprotein-2 (HDL(2))-cholesterol. In multiple regression analysis only SHBG (P = .01) and triglycerides (P = .0036) were associated with insulin sensitivity independently of body mass index (BMI), weight gain, HDL(2)-cholesterol, CRP, TNFalpha, and TNFalpha RII, IL-6, and leptin. We conclude that insulin resistance and the inflammatory markers studied were not associated in established preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536597     DOI: 10.1016/j.metabol.2004.06.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Serum adiponectin and leptin in relation to risk for preeclampsia: results from a large case-control study.

Authors:  Maria Dalamaga; Sindhu K Srinivas; Michal A Elovitz; John Chamberland; Christos S Mantzoros
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

2.  Prenatal stretching exercise and autonomic responses: preliminary data and a model for reducing preeclampsia.

Authors:  SeonAe Yeo
Journal:  J Nurs Scholarsh       Date:  2010-06       Impact factor: 3.176

3.  Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2010-03       Impact factor: 8.661

4.  Is there evidence of separate inflammatory or metabolic forms of preeclampsia?

Authors:  Sandra A Founds; Janet M Catov; Marcia J Gallaher; Gail F Harger; Nina Markovic; James M Roberts
Journal:  Hypertens Pregnancy       Date:  2010-05-12       Impact factor: 2.108

5.  Serum leptin measured in early pregnancy is higher in women with preeclampsia compared with normotensive pregnant women.

Authors:  Brandie D Taylor; Roberta B Ness; Jørn Olsen; David M Hougaard; Kristin Skogstrand; James M Roberts; Catherine L Haggerty
Journal:  Hypertension       Date:  2014-12-15       Impact factor: 10.190

6.  Insulin resistance and C-reactive protein in preeclampsia.

Authors:  Milan Stefanović; Predrag Vukomanović; Mileva Milosavljević; Ranko Kutlesić; Jasmina Popović; Aleksandra Tubić-Pavlović
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

Review 7.  Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis.

Authors:  Lisa J Alma; Anouk Bokslag; Angela H E M Maas; Arie Franx; Walter J Paulus; Christianne J M de Groot
Journal:  ESC Heart Fail       Date:  2017-01-30

8.  Association between markers of systemic inflammation, oxidative stress, lipid profiles, and insulin resistance in pregnant women.

Authors:  Zatollah Asemi; Shima Jazayeri; Mohammad Najafi; Mansooreh Samimi; Farzad Shidfar; Zohreh Tabassi; Mohamadesmaeil Shahaboddin; Ahmad Esmaillzadeh
Journal:  ARYA Atheroscler       Date:  2013-05

9.  Different profile of serum leptin between early onset and late onset preeclampsia.

Authors:  Saeedeh Salimi; Farzaneh Farajian-Mashhadi; Anoosh Naghavi; Mojgan Mokhtari; Mahnaz Shahrakipour; Mohsen Saravani; Minoo Yaghmaei
Journal:  Dis Markers       Date:  2014-01-23       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.